GlaxoSmithKline and SmithKlineBeecham File Complaint with U.S. International Trade Commission Over Clavulanic Acid Products

Summary

GlaxoSmithKline and SmithKlineBeecham have filed a complaint with the U.S. International Trade Commission alleging that certain coamoxiclav products, potassium clavulanate products, and other products derived from clavulanic acid are being imported into the US in violation of trade secrets and unfair competition, and are seeking a permanent exclusion order and cease and desist order.